Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-22T16:24:05.180Z Has data issue: false hasContentIssue false
  • English
  • Français

Radio Receptor Assay of Serum Neuroleptic Levels in Psychiatric Patients

Published online by Cambridge University Press:  29 January 2018

Janet Krska ,
G. Sampath ,
A. Shah  and
S. D. Soni
Janet Krska
Affiliation:
Department of Psychiatry, Salford Health Authority, Prestwich Hospital, Prestwich, Manchester M25 7BL
G. Sampath
Affiliation:
Department of Psychiatry, Salford Health Authority, Prestwich Hospital, Prestwich, Manchester M25 7BL
A. Shah
Affiliation:
Department of Psychiatry, Salford Health Authority, Prestwich Hospital, Prestwich, Manchester M25 7BL
S. D. Soni*
Affiliation:
Department of Psychiatry, Salford Health Authority, Prestwich Hospital, Prestwich, Manchester M25 7BL
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Abstract

The radioreceptor assay for the measurement of neuroleptic drugs in serum has been used to study the relationship between dose and serum level in schizophrenic patients receiving these drugs. The assay was found to be reproducible and capable of detecting neuroleptics in the sera of patients receiving a range of both oral and depot drugs, with the exception of trifluoperazine spansules. Linear correlations were obtained between daily dose and serum level for each drug both in individual patients on different doses and between patients on a stable dose. Extrapyramidal side effects were related to the serum neuroleptic level within, but not between, patients. The assay may be of use in clinical practice, including the assessment of compliance or poor response to neuroleptics.

Type
Papers
Information
The British Journal of Psychiatry , Volume 148 , Issue 2 , February 1986 , pp. 187 - 193
Copyright
Copyright © 1986 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Amsterdam, J., Brunswick, D. & Mendels, J. (1980) The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. American Journal of Psychiatry, 137, 653–662.Google Scholar
Brown, W. A., Laughren, T., Chisholm, E. & Williams, B. W. (1982) Low serum neuroleptic levels predict relapse in schizophrenic patients. Archives of General Psychiatry, 39, 998–1000.CrossRefGoogle ScholarPubMed
Caul, H. M., Avery, D. H., Hollister, L. E., Creese, I. & Snyder, S. H. (1979) Serum levels of neuroleptics measured by dopamine radio-receptor assay and some clinical observations. Psychiatry Research, 1, 39–44.Google Scholar
Cohen, B. M., Lipinski, J. F., Pope, H. G., Harris, P. Q. & Altesman, R. I. (1980a) Neuroleptic blood levels and therapeutic effect. Psychopharmacology, 70, 191–193.Google Scholar
Cohen, B. M., Herschel, M., Miller, E. M. & Baldessarini, R. J. (1980b) Radio-receptor assay of haloperidol tissue levels in the rat. Neuropharmacology, 19, 663–668.Google Scholar
Cohen, B. M., Lipinski, J. F., Harris, P. Q., Pope, H. G. & Friedman, M. (1980c) Clinical use of the radio-receptor assay for neuroleptics. Psychiatry Research, 1, 173–178.Google Scholar
Creese, I. & Snyder, S. H. (1977) A simple and sensitive radio-receptor assay for antischizophrenic drugs in blood. Nature, 270, 180–182.Google Scholar
Dunlop, S. R., Shea, P. A. & Hendine, H. C. (1982) The relationship between plasma and red blood cell neuroleptic levels, oral dosage and clinical parameters in a chronic schizophrenic population. Biological Psychiatry, 17, 929–936.Google Scholar
Harris, P. Q., Friedman, M. J., Cohen, B. M. & Cooper, T. B. (1982) Fluphenazine blood levels and clinical response. Biological Psychiatry. 17, 1123–1130.Google Scholar
Kolakowska, T., Wiles, D. H., Gelder, M. G. & McNeilly, A. S. (1976) Clinical significance of plasma chlorpromazine levels. Psychopharmacology, 49, 101–107.Google Scholar
Lader, S. R. (1980) A radio-receptor assay for neuroleptic drugs in plasma. Journal of Immunoassay. 1, 57–75.CrossRefGoogle Scholar
Mackay, A. V. P., Healey, A. F. & Baker, J. (1974) The relationship of plasma chlorpromazine to its 7-hydroxy-and sulphoxide metabolites in a large population of chronic schizophrenics. British Journal of Clinical Pharmacology, 1, 425–430.CrossRefGoogle Scholar
Magliozzi, J. R., Hollister, L. E., Arnold, K. V. & Earle, G. M. (1981) Relationship of serum haloperidol levels to clinical response in schizophrenic patients. American Journal of Psychiatry, 138, 365–367.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychiatric Reports, 10, 799–812.Google Scholar
Rao, V. A. R., Bishop, M. & Coppen, A. (1980) Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. British Journal of Psychiatry, 137, 518–521.CrossRefGoogle ScholarPubMed
Rivera-Calimim, L., Castaneda, L. & Lasagne, L. (1973) Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clinical Pharmacology and Therapeutics, 14, 978–986.CrossRefGoogle Scholar
Rivera-Calimim, L., Nasrallah, H., Strauss, J. & Lasagna, L. (1976) Clinical response and plasma levels: effect of dose, dosage schedules and drug interactions on plasma chlorpromazine levels. American Journal of Psychiatry, 133, 646–652.Google Scholar
Rowell, F. J., Hui, S. M., Fairburn, A. F. & Eccleston, D. (1981) Total and free serum haloperidol levels in schizophrenia patients and the effect of age, thioridazine and fatty acids on haloperidol serum protein binding in vitro . British Journal of Clinical Pharmacology, 11, 377–382.Google Scholar
Sakalis, G., Curry, S. H., Moulds, G. P. & Lader, M. D. (1972) Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clinical Pharmacology and Therapeutics, 13, 931–946.Google Scholar
Sakalis, G., Chan, T. L., Gershon, S. & Park, S. (1973) The possible role of metabolites in the therapeutic response to chlorpromazine treatment. Psychopharmacology, 32, 279–284.Google Scholar
Seeman, P., Lee, T., Chau-Wong, M. & Wong, K. (1976) Anti-psychotic drug doses and neuroleptic dopamine receptors. Nature, 261, 717–719.Google Scholar
Simpson, G. M. & Angus, J. W. S. (1970) A rating scale for extra-pyramidal side effects. Acta Psychiatrica Scandinavia, Supplement 212, 11–19.Google Scholar
Smith, R. C., Vroulis, G., Misra, C. H., Schoolar, J., DeJohn, C., Korivi, P., Leelavathi, B. E. & Ami, D. (1980) Receptor techniques in the study of plasma levels of neuroleptics and antidepressant drugs. Communications in Psychopharmacology, 4, 451–465.Google Scholar
Smith, R. C., Vroulis, G., Shuartsburd, A., Allen, R., Lewis, N., Schooler, J. C., Chojnacki, M. & Johnson, R. (1982) Red blood cell and plasma levels of haloperidol and clinical response in schizophrenia. American Journal of Psychiatry, 139, 1054–1056.Google Scholar
Tune, L. E., Creese, I., DePaulo, J. R., Slavney, P. R., Coyle, J. T. & Snyder, S. H. (1980) Clinical stete and serum neuroleptic levels measured by radioreceptor assay in schizophrenia. American Journal of Psychiatry, 137, 187–190.Google Scholar
Wiles, D. H., Kolakowska, T., McNeilly, A. S., Mandelbrote, B. M. & Gelder, M. G. (1976) Clinical significance of plasma chlorpromazine levels. I Plasma levels of the drug, some of its metabolites and prolactin during acute treatment. Psychological Medicine, 6, 407–415.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.